Barely Significant
← all excerpts

Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study.

Cancer Commun (Lond) · 2024 · PMC11666994 · PMID 39387214

Europe PMCDOI
1
hedged sentence
0.5300
closest p · 10.6× alpha
0.5300
boldest claim

The sentences

a favorable trendP = 0.53not close (p > 0.1)
The interim OS data did not suggest a favorable trend for osimertinib over placebo (36‐month OS rate, 84% vs. 74%, HR = 0.81, P = 0.53), indicating that the long‐term efficacy of LAURA treatment remains unclear.

also in 313 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.